Oral Cavity Mucosal Melanoma
2 clinical trials · Condition
◉ Watch Oral Cavity Mucosal Melanoma
| Record | Firm | Date |
|---|---|---|
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma (NCT03220009) | National Cancer Institute (NCI) | 2017-11-03 |
Track Oral Cavity Mucosal Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.